Key Players in the South Korea Hydroxychloroquine Market | Insights 2026

Key Players in the South Korea Hydroxychloroquine Market

The SouthKorea Hydroxychloroquine Market is characterized by manufacturing regulated by the Ministry of Food and Drug Safety (MFDS), and a strategic network for international distribution. Established pharmaceutical companies are focusing on the production of high-quality, disease-modifying, anti-rheumatic drugs (DMARDs), and specialized autoimmune therapies ensuring compliance with national and international requirements.

South Korea Hydroxychloroquine Market Overview

According to 6Wresearch, the South Korea hydroxychloroquine market is experiencing stable growth, on account of rising clinical focus on management of chronic autoimmune conditions, such as Systemic Lupus Erythematosus (SLE), rheumatoid arthritis and Sjogren’s syndrome. Hydroxychloroquine sulphate remains a vital drug, used in South Korea to prevent long-term joint and organ damage in patients.

The regulatory environment in South Korea is controlled by the Ministry of Food and Drug Safety, with rigorous GMP standards. This ensures a stable, high-quality supply chain for critical medicines. Moreover, the healthcare system maintains the provision of these innovative treatments across the country, due to the sophisticated local drug industry network coupled with global alliances.

Competitive Landscape

The competitive landscape of the South Korean hydroxychloroquine industry is a dynamic blend of large domestic pharmaceutical companies, and established international players. Adherence to international quality standards is a prerequisite for companies to maintain their market position. The major players focus on innovative R&D in the field of autoimmune drugs, and have a strong and efficient distribution channel between the manufacturing units and hospital clinics.

Below is a list of leading players operating in the South Korea Hydroxychloroquine Market:

1. Hanmi Pharmaceutical Co., Ltd.

Hanmi leverages its advanced R&D and manufacturing capabilities to ensure a steady supply of high-efficacy therapeutic options for chronic autoimmune care.

2. Yuhan Corporation

Yuhan maintains a deep commitment to the domestic market, focusing on the production of reliable, high-quality essential medicines.

3. Daewoong Pharmaceutical Co., Ltd.

Daewoong utilizes a highly efficient distribution infrastructure to support the widespread availability of essential autoimmune therapies.

4. Chong Kun Dang Pharmaceutical Corp.

Chong Kun Dang provides a reliable supply of essential medicines, leveraging its strong regional reach to ensure consistency for complex therapy needs.

5. GC Biopharma

GC Biopharma emphasizes patient safety and clinical efficacy, contributing significantly to the distribution of specialized autoimmune treatments.

6. Sanofi Korea

Sanofi maintains a significant footprint in South Korea, providing gold-standard formulations essential for long-term autoimmune disease management.

7. Celltrion, Inc.

Celltrion combines global manufacturing expertise with local supply chain agility to support patients requiring consistent long-term treatment.

8. LG Chem Ltd. (Life Sciences)

LG Chem focuses on developing innovative therapeutic solutions and maintaining a robust infrastructure for the distribution of essential medicines.

9. Dong-A ST Co., Ltd.

Dong-A ST is recognized for its specialized approach to therapeutic innovation and its strategic role in supplying high-quality medication to the local market.

10. Kwang Dong Pharmaceutical Co., Ltd.

Kwang Dong contributes to the stability of the autoimmune drug market by ensuring the affordability and consistent supply of essential formulations.

Key Players in the South Korea Hydroxychloroquine Market: FAQs